The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer

BACKGROUND: Osimertinib has been adopted as the standard therapy for T790M-mediated acquired resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC). The detection of EGFR T790M can be evaluated using differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Guoqiang, Chen, Kaiyan, Yu, Xiaoqing, Sheng, Jiamin, Fan, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798336/
https://www.ncbi.nlm.nih.gov/pubmed/35116599
http://dx.doi.org/10.21037/tcr-21-223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798336/
https://www.ncbi.nlm.nih.gov/pubmed/35116599
http://dx.doi.org/10.21037/tcr-21-223

Ejemplares similares